Header cover image

U.K. (FTSE) Life Sciences Industry Analysis

UpdatedNov 28, 2021
DataAggregated Company Financials
  • 7D-7.3%
  • 3M-15.6%
  • 1Y13.5%
  • YTD0.04%

Over the last 7 days, the Life Sciences industry has dropped 7.3%, driven by a decline by Oxford Nanopore Technologies of 6.8%. Meanwhile, genedrive actually outperformed within the industry, gaining 25% in the last week. This takes the industry's 12 month performance to a gain of 13%.

Industry Valuation and Performance

Has the U.K. Life Sciences Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPE
Sun, 28 Nov 2021UK£8.8bUK£844.1m-UK£191,076,906.0019.7x
Tue, 26 Oct 2021UK£7.3bUK£819.7m-UK£188,279,866.0026.1x
Thu, 23 Sep 2021UK£3.1bUK£690.4m-UK£130,420,604.0029.2x
Sat, 21 Aug 2021UK£2.9bUK£670.4m-UK£160,499,800.3562.5x
Sat, 05 Jun 2021UK£3.6bUK£670.8m-UK£88,500,847.0874.8x
Tue, 09 Mar 2021UK£3.4bUK£671.0m-UK£14,663,770.6073.6x
Mon, 30 Nov 2020UK£2.7bUK£652.1mUK£165.1m58.6x
Thu, 03 Sep 2020UK£2.5bUK£632.0mUK£378.8m48.5x
Sun, 07 Jun 2020UK£2.4bUK£617.1mUK£356.9m47x
Sat, 29 Feb 2020UK£2.2bUK£601.7mUK£316.6m46.6x
Tue, 03 Dec 2019UK£2.4bUK£581.5mUK£180.1m119.9x
Fri, 06 Sep 2019UK£2.4bUK£563.3mUK£13.6m131.7x
Mon, 10 Jun 2019UK£2.3bUK£551.8m-UK£8,998,660.86174.5x
Sun, 03 Mar 2019UK£2.0bUK£522.0m-UK£28,428,058.5950.1x
Wed, 05 Dec 2018UK£2.0bUK£495.9mUK£16.1m58.9x
PE Ratio


Total Market Cap: UK£2.0bTotal Earnings: UK£16.1mTotal Revenue: UK£495.9m0%0%0%3 Year10 Year

Current Industry PE: There are only 3 profitable companies in this industry, so there is insufficient data to make an industry-wide assessment of PE.

Past Earnings Growth: Total earnings for the Life Sciences industry have declined over the last three years, with the industry now making a loss overall. But revenues have grown 19% per year. This means that although more sales are being generated, either the cost of doing business or the level of investment back into businesses has increased, which has decreased profits.

Industry Trends

Which industries have driven the changes within the U.K. Life Sciences industry?

Clinical Research and Equipment-7.34%

Industry PE: Investors are most optimistic about the Clinical Research and Equipment industry even though it's trading below its 3-year average PE ratio of 73.1x. However analysts are expecting annual earnings growth of 11%, which is lower than the prior year's growth of 93% per year. So the market might believe that analysts are underestimating future growth.

Forecasted Growth: Analysts are most optimistic on the Clinical Research and Equipment industry, expecting annual earnings growth of 11% over the next 5 years. However this is lower than its past earnings growth rate of 93% per year.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

GDR genedrive25.4%+UK£4.3m-59.3%PS31x
FAB Fusion Antibodies4.3%+UK£1.3m13.4%PS7.6x
PRM Proteome Sciences0.9%+UK£147.6k58.5%PE42.3x
OBD Oxford BioDynamics0.2%+UK£100.4k-36.6%PS81.4x
PYC Physiomics0.8%+UK£48.7k13.8%PS8.8x
Simply Wall St
Simply Wall Street Pty Ltd
17-21 Bellevue Street, Surry Hills, Sydney
Download on the App StoreGet it on Google Play
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.

Latest News